Parameter
| Biomarker | CgA | Full name | Chromogranin A | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Diagnosis, monitoring and prognosis |
| Disease | Pancreatic Neuroendocrine Tumors | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum/plasma (immune analysis method, ELISA) | ||
| Pathobiological Mechanisms | Particles of the neuroendocrine cells secrete proteins, tumor progression, released when reflect the tumor load | ||||
| Clinical Availability Status | Routine clinical application: PanNENs screening, disease progression monitoring and treatment response evaluation; 60-83% sensitivity and specificity of 72-85%, need to rule out the use of interference factors such as renal insufficiency, PPI | ||||
| Notes and Dynamics | And NSE joint detection can improve the prognosis assessment accuracy, is by far the most commonly used general serum marker | ||||